Knight Therapeutics (GUD) Q4 2024 earnings summary

Executive summary

• Achieved record revenues in 2024, reaching over CAD 365 million ($371.3M), up 13% year-over-year, driven by promoted products and hyperinflation in Argentina, with adjusted EBITDA of approximately CAD 58 million.

• Promoted portfolio grew 16% year-over-year, with a three-year CAGR exceeding 30%; five new products added to the pipeline.

• Net income reached $4.3M versus a net loss of $16.8M in 2023; EPS improved to $0.04 from a loss of $0.16.

• Expanded neurology and oncology portfolios through licensing, partnerships, and regulatory approvals across Canada and LATAM.

• Announced Paladin acquisition for $120M upfront, expected to close mid-2025, adding scale and cash flow in Canada.

Financial highlights

• 2024 revenues reached over CAD 365 million ($371.3M), up 6–13% year-over-year; Q4 revenues were over CAD 94 million ($96.9M), up 6–31% from prior year.

• Oncology and hematology portfolio delivered CAD 137.6 million, up 12% year-over-year; infectious diseases portfolio delivered $149 million, up 6–10%.

• Gross margin for 2024 was 47% of revenues, slightly down or flat year-over-year due to product mix.

• Adjusted EBITDA for 2024 was CAD 57.8 million ($57.8M), down 4% year-over-year; adjusted EBITDA per share was CAD 0.58 ($0.58), down 0–2%.

• Cash inflow from operations totaled $36 million, with cash and marketable securities at year-end of $142.3M, down 12%.

Outlook and guidance

• 2025 revenue guidance: CAD 390–405 million ($390M–$405M); adjusted EBITDA expected at approximately 13% of revenues, reflecting investments in new launches and pipeline advancement.

• Guidance assumes Paladin acquisition closes mid-2025 and no major disruptions or new generic entrants.

• More than half of the CAD 150 million peak sales potential from the pipeline is attributable to near-term launches.

• Profitability from new launches typically achieved by the third year post-launch.